EXACT Sciences (NASDAQ:EXAS) PT Lowered to $105.00

Share on StockTwits

EXACT Sciences (NASDAQ:EXAS) had its price objective trimmed by Leerink Swann from $133.00 to $105.00 in a research note issued to investors on Wednesday, October 30th, The Fly reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Other analysts also recently issued research reports about the company. UBS Group lifted their price objective on EXACT Sciences from $120.00 to $143.00 and gave the stock a buy rating in a research note on Thursday, August 1st. ValuEngine downgraded EXACT Sciences from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Canaccord Genuity reduced their price objective on EXACT Sciences from $135.00 to $120.00 and set a buy rating on the stock in a research note on Wednesday, October 30th. Cowen lifted their price objective on EXACT Sciences from $125.00 to $135.00 and gave the stock an outperform rating in a research note on Monday, July 29th. They noted that the move was a valuation call. Finally, Oppenheimer started coverage on EXACT Sciences in a research report on Thursday, September 26th. They set an outperform rating and a $130.00 target price on the stock. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $124.69.

EXAS traded up $3.71 during midday trading on Wednesday, hitting $83.66. The stock had a trading volume of 2,824,000 shares, compared to its average volume of 1,831,696. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.75. EXACT Sciences has a 1 year low of $53.06 and a 1 year high of $123.99. The business has a fifty day moving average of $92.42 and a 200 day moving average of $105.67. The company has a market cap of $10.94 billion, a P/E ratio of -61.51 and a beta of 1.37.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, October 29th. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.10. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. The business had revenue of $218.81 million for the quarter, compared to the consensus estimate of $216.14 million. During the same quarter in the previous year, the company posted ($0.37) EPS. The company’s revenue was up 85.0% compared to the same quarter last year. On average, equities research analysts anticipate that EXACT Sciences will post -1.63 earnings per share for the current year.

In related news, SVP Scott C. Johnson sold 3,527 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $108.63, for a total transaction of $383,138.01. Following the completion of the transaction, the senior vice president now owns 7,934 shares in the company, valued at approximately $861,870.42. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 2.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC boosted its holdings in EXACT Sciences by 216.9% during the 2nd quarter. Jennison Associates LLC now owns 3,303,930 shares of the medical research company’s stock valued at $389,996,000 after acquiring an additional 2,261,394 shares during the period. Stephens Inc. AR boosted its holdings in EXACT Sciences by 59.5% during the 2nd quarter. Stephens Inc. AR now owns 3,827 shares of the medical research company’s stock valued at $452,000 after acquiring an additional 1,427 shares during the period. Daiwa Securities Group Inc. purchased a new stake in shares of EXACT Sciences in the 2nd quarter worth $561,000. First Republic Investment Management Inc. lifted its holdings in shares of EXACT Sciences by 19.3% in the 2nd quarter. First Republic Investment Management Inc. now owns 5,851 shares of the medical research company’s stock worth $691,000 after buying an additional 946 shares during the period. Finally, ACG Wealth purchased a new stake in shares of EXACT Sciences in the 2nd quarter worth $236,000. Institutional investors own 87.09% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Featured Story: How does inflation affect different investments?

The Fly

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.